Thoratec Collects LVAD Cost Data In Support Of Medicare Reimbursement
This article was originally published in The Gray Sheet
Executive Summary
Thoratec is confident its HeartMate VE left ventricular assist device will secure adequate reimbursement by Medicare despite its relatively high cost because it is associated with higher survival rates and quality of life scores than current medical alternatives